Objective. The relationship between survival and early changes in the serum level of the CA-125 antigen in patients with advanced ovarian cancer remains poorly defined. Methods. To explore this issue, the serum CA-125 values from 101 patients with advanced ovarian cancer who participated in a Southwest Oncology Group trial (SWOG 8412), which compared the systemic delivery of cisplatin/cyclophosphamide vs. carboplatin/cyclophosphamide (both delivered every 28 days for 6 cycles) in suboptimal residual stage III and IV ovarian cancer, were evaluated. All patients in this analysis had CA-125 values available for at least 8 weeks following initiation of chemotherapy. Cox proportional hazards regression was used in multivariate analysis to determine the prognostic significance of the CA-125 concentration. Results. While pretreatment CA-125 values did not correlate with survival, the concentration of this tumor marker 8 weeks after initiation of therapy was a powerful independent prognostic factor. The median survivals for patients (n = 51) with a CA-125 < 35 U/ml, vs. patients (n = 50) with a CA-125 > 35 U/ml, at this time point, were 26 months and 15 months, respectively (P = 0.0001). Further, women with serum CA-125 values < 50% of their pretreatment concentration at 8 weeks experienced a median survival of 21 months, compared to only 10 months for individuals with tumor marker levels > 50% of their baseline value (P = 0.0003). Conclusion. Reduction in the serum CA-125 concentration over the initial two cycles of platinum-based chemotherapy is a powerful independent predictor of survival for patients with suboptimal stage III or IV ovarian cancer. Patients without significant declines in CA-125 after two cycles of platinum-based chemotherapy have a particularly poor prognosis. (c) 2006 Elsevier Inc. All rights reserved.
|Data di pubblicazione:||2006|
|Titolo:||Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer|
|Autore/i:||Markman, M; Federico, Massimo; Liu, Py; Hannigan, E; Alberts, D.|
|Digital Object Identifier (DOI):||10.1016/j.ygyno.2006.02.024|
|Codice identificativo ISI:||WOS:000240887100037|
|Codice identificativo Scopus:||2-s2.0-33748708039|
|Codice identificativo Pubmed:||16595148|
|Citazione:||Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer / Markman M; Federico M; Liu PY; Hannigan E; Alberts D. - In: GYNECOLOGIC ONCOLOGY. - ISSN 0090-8258. - STAMPA. - 103 (1)(2006), pp. 195-198.|
|Tipologia||Articolo su rivista|
I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris